Products
Umizortamig Biosimilar Tetraspecific Antibody (EGFRvIII × CD3 × PD-L1 × 4-1BB) for Research
Cat No.: GMP-Bios-INN-1440
Anti-EGFRvIII therapeutic antibody (Pre-made Umizortamig biosimilar,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Umizortamig (development code GNC-039) is a tetraspecific antibody targeting EGFRvIII and CD3. It is developed by Sichuan Baili Pharmaceutical Co., Ltd. for Recurrent Glioma, Solid Tumor in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1440-1mg | 1mg | |
| GMP-Bios-INN-1440-10mg | 10mg | |
| GMP-Bios-INN-1440-100mg | 100mg | |
| GMP-Bios-INN-1440-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Umizortamig biosimilar, Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1), Anti-EGFRvIII;CD3E;PDL1/CD274;TNFRSF9/CD137/4-1BB Antibody: Anti-EGFR vIII/Epidermal growth factor receptor/Proto-oncogene c-ErbB-1/Receptor tyrosine-protein kinase erbB-1 therapeutic antibody |
| INN Name | Umizortamig |
| Target | EGFRvIII;CD3E;PDL1/CD274;TNFRSF9/CD137/4-1BB |
| Format | Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1) |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;3g5x:DC:BA |
| 95-98% SI Structure | None;3g5v:BA/3g5z:BA |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | na |
